Nasal stack protocols: separation, rotation, and receptor management

Researchers working with peptides by injection can effectively treat each compound as an independent pharmacokinetic input — solvent volume is generous, absorption is complete, and there is no shared delivery substrate. The intranasal route does not permit that simplification. The nasal mucosa is a finite, dynamically clearing delivery surface, and two compounds administered in the same nasal session are sharing absorption area, mucoadhesive residence time, and the attention of the mucociliary escalator that clears them.

This entry summarizes the published delivery-mechanics literature relevant to multi-peptide protocol design and then applies it to the specific combinations most commonly encountered with the four compounds we catalog: BPC-157, Selank, Semax, and PT-141. No formal pharmacokinetic interaction studies exist for these pairs; what follows is informed protocol design drawing on nasal-delivery science and published single- compound studies.

Three constraints from the nasal-delivery literature are central to multi-peptide protocol design:

1. Mucociliary clearance. The nasal mucosa clears deposited material at roughly 5-6 mm per minute, which translates to a residence time on the order of 15-20 minutes for most of the deposited dose [1, 4]. Administering a second peptide immediately after the first risks co-delivery into the same clearance wave and competition for absorption windows.

2. Absorption surface saturation. The effective absorption area of the respiratory epithelium is limited, and formulation volume per nostril per administration is bounded. Dhuria and colleagues reviewed the mechanisms and noted that concentration gradients across the mucosa drive absorption, which means two compounds competing for transport at the same site can depress each other’s effective bioavailability [3, 5].

3. Olfactory/trigeminal pathway access. For CNS-targeted compounds (Selank, Semax, PT-141 centrally), the olfactory and trigeminal pathways described by Born et al. and Dhuria et al. provide direct access to brain tissue without first entering the systemic circulation [2, 3]. This pathway is anatomically localized to the olfactory cleft in the upper nasal cavity. Deposition technique — head tilt, atomizer geometry, inspiration coordination — matters more for these compounds than for systemic nasal delivery.

The honest answer is: not very much, with specificity. Formal pharmacokinetic interaction studies between the research peptides discussed here have not been published. The combinations encountered in Russian clinical literature — principally Selank with Semax — are described at the protocol level (“peptide A in morning, peptide B in evening”) rather than at the PK-interaction level [7].

What is well characterized is the general behavior of the nasal delivery route under the Illum, Dhuria, and Lochhead/Thorne reviews [1, 3, 5]. These provide the framework researchers apply to protocol design: separation in time rather than mixture in formulation, alternation of nostrils when back-to-back administration is unavoidable, and respect for mucociliary clearance as a real pharmacological variable.

Gänger and Schindowski (2018) provide a more recent synthesis focused specifically on nose-to-brain delivery formulation design, including the physicochemical properties that favor olfactory pathway uptake [6]. Their review is relevant for researchers choosing formulation vehicles for the CNS-targeted peptides in the catalog (Selank, Semax, and the central components of PT-141 action).

Building on the three mechanical constraints above, a few protocol heuristics recur in researcher practice:

Separate dose windows by at least 30-60 minutes. This clears the mucociliary residence window for the first compound and allows mucosal vascular flow to reset. For compounds with rapid onset (Selank, Semax), the pharmacodynamic effect can also be partially assessed before a second compound is added.

Alternate nostrils. When two compounds must be administered in the same session (for example, in protocols that combine morning dosing of Selank and Semax), administering one per nostril reduces direct competition for absorption surface. This is a mitigation, not a solution, and does not substitute for temporal separation where the goal is to isolate effects.

Rotate weekly rather than stack daily. For some researcher protocols, particularly with compounds that have residual pharmacodynamic effects over days (Semax’s neurotrophic induction, for example), a block-rotation design — two weeks of compound A, two weeks of compound B — is considered more interpretable than parallel daily stacking.

Watch for receptor-family overlap. The non-overlap of mechanisms is part of why the BPC-157 / Selank / Semax / PT-141 combination is a commonly-studied set: each targets a distinct system (angiogenic, GABAergic, neurotrophic, melanocortin). Stacks that combine two melanocortin-active peptides, or two direct GABA-A ligands, are actively avoided in well-designed research protocols because the overlapping receptor pharmacology produces interpretability problems and, in some combinations, additive safety concerns.

A practical summary for the four peptides in our catalog:

• BPC-157 + Selank — mechanism-orthogonal (angiogenic/somatic vs. GABAergic/CNS). No pharmacological interaction expected. Typical protocol: separate by 30-60 minutes, alternate nostrils if same session.
• BPC-157 + Semax — mechanism-orthogonal (angiogenic/somatic vs. neurotrophic/CNS). Similar separation recommendation.
• Selank + Semax — the canonical Russian-literature pairing. Mechanism-orthogonal within the CNS (GABAergic vs. neurotrophic). Well-represented in combined clinical protocols [7]. Standard practice is morning Semax, evening Selank, or vice versa.
• PT-141 standalone — the melanocortin activity profile and the cardiovascular/nausea side- effect pattern make this a compound typically studied in episodic rather than daily dosing, which reduces stack-combination relevance. See PT-141 entry.
• Anti-pairing: any two melanocortin agonists. PT-141 with Melanotan II, for example, combines overlapping receptor activity and potential additive pressor and pigmentation effects. Avoided in structured protocols.
• Anti-pairing: Selank with direct GABA-A ligands (benzodiazepines, alcohol). The interaction space is uncharacterized. While Selank’s mechanism is transcriptional rather than allosteric, no formal interaction study exists, and protocol design should avoid the combination.